Mosunetuzumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Mosunetuzumab" in English language version.

refsWebsite

Global rank English rank

8web.archive.org

1^st place

4fda.gov

447^th place

338^th place

3europa.eu

68^th place

117^th place

2handelszeitung.ch

7,752^nd place

low place

2nih.gov

4^th place

1nature.com

234^th place

397^th place

1doi.org

2^nd place

1semanticscholar.org

11^th place

8^th place

1handle.net

102^nd place

76^th place

1tagesanzeiger.ch

2,194^th place

5,555^th place

1srf.ch

1,487^th place

4,554^th place

doi.org

Carvalho T (March 2023). "FDA approves Genentech's bispecific antibody for lymphoma". Nature Medicine. 29 (3): 507–508. doi:10.1038/d41591-023-00010-0. PMID 36697979. S2CID 256273270. Archived from the original on 6 February 2023. Retrieved 6 February 2023.

europa.eu

ema.europa.eu

"Lunsumio EPAR". European Medicines Agency (EMA). 13 April 2022. Archived from the original on 4 January 2023. Retrieved 3 January 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Lunsumio: Pending EC decision". European Medicines Agency (EMA). 22 April 2022. Archived from the original on 22 April 2022. Retrieved 22 April 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

ec.europa.eu

"Lunsumio Product information". Union Register of medicinal products. Retrieved 3 March 2023.

fda.gov

"FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma". U.S. Food and Drug Administration (FDA). 22 December 2022. Archived from the original on 4 January 2023. Retrieved 3 January 2023. This article incorporates text from this source, which is in the public domain.
"Advancing Health Through Innovation: New Drug Therapy Approvals 2022". U.S. Food and Drug Administration (FDA). 10 January 2023. Archived from the original on 21 January 2023. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.
New Drug Therapy Approvals 2022 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 14 January 2024. Retrieved 14 January 2024. This article incorporates text from this source, which is in the public domain.

accessdata.fda.gov

"Lunsumio: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 4 January 2023. Retrieved 3 January 2023.

handelszeitung.ch

"Roche vs. BAG – der Kanarienvogel in der Mine". Handelszeitung (in Swiss High German). Retrieved 25 July 2025.
"Krebstherapie in Gefahr: Roche-Medikament aus dem Markt genommen". Handelszeitung (in Swiss High German). Retrieved 25 July 2025.

handle.net

hdl.handle.net

World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 79". WHO Drug Information. 32 (1). hdl:10665/330941.

nature.com

Carvalho T (March 2023). "FDA approves Genentech's bispecific antibody for lymphoma". Nature Medicine. 29 (3): 507–508. doi:10.1038/d41591-023-00010-0. PMID 36697979. S2CID 256273270. Archived from the original on 6 February 2023. Retrieved 6 February 2023.

nih.gov

dailymed.nlm.nih.gov

"Lunsumio- mosunetuzumab concentrate". DailyMed. 22 December 2022. Archived from the original on 21 January 2023. Retrieved 21 January 2023.

pubmed.ncbi.nlm.nih.gov

Carvalho T (March 2023). "FDA approves Genentech's bispecific antibody for lymphoma". Nature Medicine. 29 (3): 507–508. doi:10.1038/d41591-023-00010-0. PMID 36697979. S2CID 256273270. Archived from the original on 6 February 2023. Retrieved 6 February 2023.

semanticscholar.org

api.semanticscholar.org

Carvalho T (March 2023). "FDA approves Genentech's bispecific antibody for lymphoma". Nature Medicine. 29 (3): 507–508. doi:10.1038/d41591-023-00010-0. PMID 36697979. S2CID 256273270. Archived from the original on 6 February 2023. Retrieved 6 February 2023.

srf.ch

"BAG-Streit: Roche zieht Krebsmedikament Lunsumio zurück". Schweizer Radio und Fernsehen (SRF) (in German). Retrieved 25 July 2025.

tagesanzeiger.ch

Peterhans, Anielle; Boss, Catherine. "Roche zieht Krebsmedikament zurück: «Der Kampf ums Geld wird auf dem Rücken schwer kranker Menschen ausgetragen»". Tages-Anzeiger (in German). Retrieved 25 July 2025.

web.archive.org

"Lunsumio- mosunetuzumab concentrate". DailyMed. 22 December 2022. Archived from the original on 21 January 2023. Retrieved 21 January 2023.
"FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma". U.S. Food and Drug Administration (FDA). 22 December 2022. Archived from the original on 4 January 2023. Retrieved 3 January 2023. This article incorporates text from this source, which is in the public domain.
"Lunsumio EPAR". European Medicines Agency (EMA). 13 April 2022. Archived from the original on 4 January 2023. Retrieved 3 January 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Lunsumio: Pending EC decision". European Medicines Agency (EMA). 22 April 2022. Archived from the original on 22 April 2022. Retrieved 22 April 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
Carvalho T (March 2023). "FDA approves Genentech's bispecific antibody for lymphoma". Nature Medicine. 29 (3): 507–508. doi:10.1038/d41591-023-00010-0. PMID 36697979. S2CID 256273270. Archived from the original on 6 February 2023. Retrieved 6 February 2023.
"Lunsumio: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 4 January 2023. Retrieved 3 January 2023.
"Advancing Health Through Innovation: New Drug Therapy Approvals 2022". U.S. Food and Drug Administration (FDA). 10 January 2023. Archived from the original on 21 January 2023. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.
New Drug Therapy Approvals 2022 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 14 January 2024. Retrieved 14 January 2024. This article incorporates text from this source, which is in the public domain.